Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $691,900.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $69.19, for a total transaction of $691,900.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $53,122,698.20. The trade was a 1.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Tuesday, May 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $71.75, for a total value of $1,435,000.00.
• On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.50, for a total value of $635,000.00.
• On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $64.24, for a total value of $1,284,800.00.
• On Wednesday, March 4th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $70.21, for a total value of $702,100.00.
• On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.69, for a total value of $1,393,800.00.

Halozyme Therapeutics Trading Down 3.0%

Halozyme Therapeutics stock opened at $67.12 on Friday. The company has a quick ratio of 3.66, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a 52 week low of $48.64 and a 52 week high of $82.22. The company has a market capitalization of $7.96 billion, a price-to-earnings ratio of 24.14, a price-to-earnings-growth ratio of 0.28 and a beta of 0.89. The stock has a 50-day moving average price of $65.65 and a 200 day moving average price of $68.64.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. During the same quarter in the previous year, the company posted $1.11 earnings per share. The company’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.66 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Benchmark lifted their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. HC Wainwright lifted their price target on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Morgan Stanley lowered their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $80.67.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SummitTX Capital L.P. acquired a new position in Halozyme Therapeutics during the first quarter worth $876,000. Corsair Capital Management L.P. acquired a new position in Halozyme Therapeutics during the first quarter worth $646,000. OMERS ADMINISTRATION Corp boosted its stake in Halozyme Therapeutics by 47.3% during the first quarter. OMERS ADMINISTRATION Corp now owns 73,789 shares of the biopharmaceutical company’s stock worth $4,769,000 after buying an additional 23,700 shares during the last quarter. Epoch Investment Partners Inc. boosted its stake in Halozyme Therapeutics by 113.4% during the first quarter. Epoch Investment Partners Inc. now owns 1,138,377 shares of the biopharmaceutical company’s stock worth $73,573,000 after buying an additional 605,018 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Halozyme Therapeutics by 30.1% during the first quarter. Renaissance Technologies LLC now owns 731,811 shares of the biopharmaceutical company’s stock worth $47,297,000 after buying an additional 169,100 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.